#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Diy_coref|
#T_RL=webanno.custom.Diy_coref_re|BT_webanno.custom.Diy_coref


#Text=[0095] 2.
1-1	0-1	[	_	_	
1-2	1-5	0095	_	_	
1-3	5-6	]	_	_	
1-4	7-8	2	_	_	
1-5	8-9	.	_	_	

#Text=Viral Pathogens
#Text=[0096] The methods of the invention are also useful for obtaining recombinant nucleic acids and polypeptides that have enhanced ability to induce an immune response against viral pathogens.
2-1	10-15	Viral	_	_	
2-2	16-25	Pathogens	_	_	
2-3	26-27	[	_	_	
2-4	27-31	0096	_	_	
2-5	31-32	]	_	_	
2-6	33-36	The	_	_	
2-7	37-44	methods	_	_	
2-8	45-47	of	_	_	
2-9	48-51	the	_	_	
2-10	52-61	invention	_	_	
2-11	62-65	are	_	_	
2-12	66-70	also	_	_	
2-13	71-77	useful	_	_	
2-14	78-81	for	_	_	
2-15	82-91	obtaining	_	_	
2-16	92-103	recombinant	_	_	
2-17	104-111	nucleic	_	_	
2-18	112-117	acids	_	_	
2-19	118-121	and	_	_	
2-20	122-134	polypeptides	_	_	
2-21	135-139	that	_	_	
2-22	140-144	have	_	_	
2-23	145-153	enhanced	_	_	
2-24	154-161	ability	_	_	
2-25	162-164	to	_	_	
2-26	165-171	induce	_	_	
2-27	172-174	an	_	_	
2-28	175-181	immune	_	_	
2-29	182-190	response	_	_	
2-30	191-198	against	_	_	
2-31	199-204	viral	_	_	
2-32	205-214	pathogens	_	_	
2-33	214-215	.	_	_	

#Text=While the bacterial recombinants described above are typically administered in polypeptide form, recombinants that confer viral protection are preferably administered in nucleic acid form, as genetic vaccines.
#Text=[0097] One illustrative example is the Hantaan virus.
3-1	216-221	While	_	_	
3-2	222-225	the	_	_	
3-3	226-235	bacterial	_	_	
3-4	236-248	recombinants	_	_	
3-5	249-258	described	_	_	
3-6	259-264	above	_	_	
3-7	265-268	are	_	_	
3-8	269-278	typically	_	_	
3-9	279-291	administered	_	_	
3-10	292-294	in	_	_	
3-11	295-306	polypeptide	_	_	
3-12	307-311	form	_	_	
3-13	311-312	,	_	_	
3-14	313-325	recombinants	_	_	
3-15	326-330	that	_	_	
3-16	331-337	confer	_	_	
3-17	338-343	viral	_	_	
3-18	344-354	protection	_	_	
3-19	355-358	are	_	_	
3-20	359-369	preferably	_	_	
3-21	370-382	administered	_	_	
3-22	383-385	in	_	_	
3-23	386-393	nucleic	_	_	
3-24	394-398	acid	_	_	
3-25	399-403	form	_	_	
3-26	403-404	,	_	_	
3-27	405-407	as	_	_	
3-28	408-415	genetic	_	_	
3-29	416-424	vaccines	_	_	
3-30	424-425	.	_	_	
3-31	426-427	[	_	_	
3-32	427-431	0097	_	_	
3-33	431-432	]	_	_	
3-34	433-436	One	_	_	
3-35	437-449	illustrative	_	_	
3-36	450-457	example	_	_	
3-37	458-460	is	_	_	
3-38	461-464	the	_	_	
3-39	465-472	Hantaan	_	_	
3-40	473-478	virus	_	_	
3-41	478-479	.	_	_	

#Text=Glycoproteins of this virus typically accumulate at the membranes of the Golgi apparatus of infected cells.
4-1	480-493	Glycoproteins	_	_	
4-2	494-496	of	_	_	
4-3	497-501	this	_	_	
4-4	502-507	virus	_	_	
4-5	508-517	typically	_	_	
4-6	518-528	accumulate	_	_	
4-7	529-531	at	_	_	
4-8	532-535	the	_	_	
4-9	536-545	membranes	_	_	
4-10	546-548	of	_	_	
4-11	549-552	the	_	_	
4-12	553-558	Golgi	_	_	
4-13	559-568	apparatus	_	_	
4-14	569-571	of	_	_	
4-15	572-580	infected	_	_	
4-16	581-586	cells	_	_	
4-17	586-587	.	_	_	

#Text=This poor expression of the glycoprotein prevents the development of efficient genetic vaccines against these viruses.
5-1	588-592	This	*[1]	6-7[2_1]	
5-2	593-597	poor	*[1]	_	
5-3	598-608	expression	*[1]	_	
5-4	609-611	of	*[1]	_	
5-5	612-615	the	*[1]	_	
5-6	616-628	glycoprotein	*[1]	_	
5-7	629-637	prevents	*[1]	_	
5-8	638-641	the	*[1]	_	
5-9	642-653	development	*[1]	_	
5-10	654-656	of	*[1]	_	
5-11	657-666	efficient	*[1]	_	
5-12	667-674	genetic	*[1]	_	
5-13	675-683	vaccines	*[1]	_	
5-14	684-691	against	*[1]	_	
5-15	692-697	these	*[1]	_	
5-16	698-705	viruses	*[1]	_	
5-17	705-706	.	*[1]	_	

#Text=The methods of the invention solve this problem by performing DNA shuffling on nucleic acids that encode the glycoproteins and identifying those recombinants that exhibit enhanced expression in a host cell, and/or for improved immunogenicity when administered as a genetic vaccine.
6-1	707-710	The	_	_	
6-2	711-718	methods	_	_	
6-3	719-721	of	_	_	
6-4	722-725	the	_	_	
6-5	726-735	invention	_	_	
6-6	736-741	solve	_	_	
6-7	742-746	this	*[2]	_	
6-8	747-754	problem	*[2]	_	
6-9	755-757	by	_	_	
6-10	758-768	performing	_	_	
6-11	769-772	DNA	_	_	
6-12	773-782	shuffling	_	_	
6-13	783-785	on	_	_	
6-14	786-793	nucleic	_	_	
6-15	794-799	acids	_	_	
6-16	800-804	that	_	_	
6-17	805-811	encode	_	_	
6-18	812-815	the	_	_	
6-19	816-829	glycoproteins	_	_	
6-20	830-833	and	_	_	
6-21	834-845	identifying	_	_	
6-22	846-851	those	_	_	
6-23	852-864	recombinants	_	_	
6-24	865-869	that	_	_	
6-25	870-877	exhibit	_	_	
6-26	878-886	enhanced	_	_	
6-27	887-897	expression	_	_	
6-28	898-900	in	_	_	
6-29	901-902	a	_	_	
6-30	903-907	host	_	_	
6-31	908-912	cell	_	_	
6-32	912-913	,	_	_	
6-33	914-917	and	_	_	
6-34	917-918	/	_	_	
6-35	918-920	or	_	_	
6-36	921-924	for	_	_	
6-37	925-933	improved	_	_	
6-38	934-948	immunogenicity	_	_	
6-39	949-953	when	_	_	
6-40	954-966	administered	_	_	
6-41	967-969	as	_	_	
6-42	970-971	a	_	_	
6-43	972-979	genetic	_	_	
6-44	980-987	vaccine	_	_	
6-45	987-988	.	_	_	

#Text=A convenient screening method for these methods is to express the recombinant polynucleotides as fusion proteins to PIG, which results in display of the polypeptides on the surface of the host cell (Whitehorn et al. (1995) Biotechnology (NY) 13:1215-9).
7-1	989-990	A	_	_	
7-2	991-1001	convenient	_	_	
7-3	1002-1011	screening	_	_	
7-4	1012-1018	method	_	_	
7-5	1019-1022	for	_	_	
7-6	1023-1028	these	_	_	
7-7	1029-1036	methods	_	_	
7-8	1037-1039	is	_	_	
7-9	1040-1042	to	_	_	
7-10	1043-1050	express	_	_	
7-11	1051-1054	the	_	_	
7-12	1055-1066	recombinant	_	_	
7-13	1067-1082	polynucleotides	_	_	
7-14	1083-1085	as	_	_	
7-15	1086-1092	fusion	_	_	
7-16	1093-1101	proteins	_	_	
7-17	1102-1104	to	_	_	
7-18	1105-1108	PIG	_	_	
7-19	1108-1109	,	_	_	
7-20	1110-1115	which	_	_	
7-21	1116-1123	results	_	_	
7-22	1124-1126	in	_	_	
7-23	1127-1134	display	_	_	
7-24	1135-1137	of	_	_	
7-25	1138-1141	the	_	_	
7-26	1142-1154	polypeptides	_	_	
7-27	1155-1157	on	_	_	
7-28	1158-1161	the	_	_	
7-29	1162-1169	surface	_	_	
7-30	1170-1172	of	_	_	
7-31	1173-1176	the	_	_	
7-32	1177-1181	host	_	_	
7-33	1182-1186	cell	_	_	
7-34	1187-1188	(	_	_	
7-35	1188-1197	Whitehorn	_	_	
7-36	1198-1200	et	_	_	
7-37	1201-1203	al	_	_	
7-38	1203-1204	.	_	_	
7-39	1205-1206	(	_	_	
7-40	1206-1210	1995	_	_	
7-41	1210-1211	)	_	_	
7-42	1212-1225	Biotechnology	_	_	
7-43	1226-1227	(	_	_	
7-44	1227-1229	NY	_	_	
7-45	1229-1230	)	_	_	
7-46	1231-1233	13	_	_	
7-47	1233-1234	:	_	_	
7-48	1234-1238	1215	_	_	
7-49	1238-1239	-	_	_	
7-50	1239-1240	9	_	_	
7-51	1240-1241	)	_	_	
7-52	1241-1242	.	_	_	

#Text=Fluorescence-activated cell sorting is then used to sort and recover those cells that express an increased amount of the antigenic polypeptide on the cell surface.
8-1	1243-1265	Fluorescence-activated	_	_	
8-2	1266-1270	cell	_	_	
8-3	1271-1278	sorting	_	_	
8-4	1279-1281	is	_	_	
8-5	1282-1286	then	_	_	
8-6	1287-1291	used	_	_	
8-7	1292-1294	to	_	_	
8-8	1295-1299	sort	_	_	
8-9	1300-1303	and	_	_	
8-10	1304-1311	recover	_	_	
8-11	1312-1317	those	_	_	
8-12	1318-1323	cells	_	_	
8-13	1324-1328	that	_	_	
8-14	1329-1336	express	_	_	
8-15	1337-1339	an	_	_	
8-16	1340-1349	increased	_	_	
8-17	1350-1356	amount	_	_	
8-18	1357-1359	of	_	_	
8-19	1360-1363	the	_	_	
8-20	1364-1373	antigenic	_	_	
8-21	1374-1385	polypeptide	_	_	
8-22	1386-1388	on	_	_	
8-23	1389-1392	the	_	_	
8-24	1393-1397	cell	_	_	
8-25	1398-1405	surface	_	_	
8-26	1405-1406	.	_	_	

#Text=This preliminary screen can be followed by immunogenicity tests in mammals, such as mice.
9-1	1407-1411	This	_	_	
9-2	1412-1423	preliminary	_	_	
9-3	1424-1430	screen	_	_	
9-4	1431-1434	can	_	_	
9-5	1435-1437	be	_	_	
9-6	1438-1446	followed	_	_	
9-7	1447-1449	by	_	_	
9-8	1450-1464	immunogenicity	_	_	
9-9	1465-1470	tests	_	_	
9-10	1471-1473	in	_	_	
9-11	1474-1481	mammals	_	_	
9-12	1481-1482	,	_	_	
9-13	1483-1487	such	_	_	
9-14	1488-1490	as	_	_	
9-15	1491-1495	mice	_	_	
9-16	1495-1496	.	_	_	

#Text=Finally, in preferred embodiments, those recombinant nucleic acids are tested as genetic vaccines for their ability to protect a test animal against challenge by the virus.
#Text=[0098] The flaviviruses are another example of a viral pathogen for which the methods of the invention are useful for obtaining a recombinant polypeptide or genetic vaccine that is effective against a viral pathogen.
10-1	1497-1504	Finally	_	_	
10-2	1504-1505	,	_	_	
10-3	1506-1508	in	_	_	
10-4	1509-1518	preferred	_	_	
10-5	1519-1530	embodiments	_	_	
10-6	1530-1531	,	_	_	
10-7	1532-1537	those	_	_	
10-8	1538-1549	recombinant	_	_	
10-9	1550-1557	nucleic	_	_	
10-10	1558-1563	acids	_	_	
10-11	1564-1567	are	_	_	
10-12	1568-1574	tested	_	_	
10-13	1575-1577	as	_	_	
10-14	1578-1585	genetic	_	_	
10-15	1586-1594	vaccines	_	_	
10-16	1595-1598	for	_	_	
10-17	1599-1604	their	_	_	
10-18	1605-1612	ability	_	_	
10-19	1613-1615	to	_	_	
10-20	1616-1623	protect	_	_	
10-21	1624-1625	a	_	_	
10-22	1626-1630	test	_	_	
10-23	1631-1637	animal	_	_	
10-24	1638-1645	against	_	_	
10-25	1646-1655	challenge	_	_	
10-26	1656-1658	by	_	_	
10-27	1659-1662	the	_	_	
10-28	1663-1668	virus	_	_	
10-29	1668-1669	.	_	_	
10-30	1670-1671	[	_	_	
10-31	1671-1675	0098	_	_	
10-32	1675-1676	]	_	_	
10-33	1677-1680	The	_	_	
10-34	1681-1693	flaviviruses	_	_	
10-35	1694-1697	are	_	_	
10-36	1698-1705	another	_	_	
10-37	1706-1713	example	_	_	
10-38	1714-1716	of	_	_	
10-39	1717-1718	a	_	_	
10-40	1719-1724	viral	_	_	
10-41	1725-1733	pathogen	_	_	
10-42	1734-1737	for	_	_	
10-43	1738-1743	which	_	_	
10-44	1744-1747	the	_	_	
10-45	1748-1755	methods	_	_	
10-46	1756-1758	of	_	_	
10-47	1759-1762	the	_	_	
10-48	1763-1772	invention	_	_	
10-49	1773-1776	are	_	_	
10-50	1777-1783	useful	_	_	
10-51	1784-1787	for	_	_	
10-52	1788-1797	obtaining	_	_	
10-53	1798-1799	a	_	_	
10-54	1800-1811	recombinant	_	_	
10-55	1812-1823	polypeptide	_	_	
10-56	1824-1826	or	_	_	
10-57	1827-1834	genetic	_	_	
10-58	1835-1842	vaccine	_	_	
10-59	1843-1847	that	_	_	
10-60	1848-1850	is	_	_	
10-61	1851-1860	effective	_	_	
10-62	1861-1868	against	_	_	
10-63	1869-1870	a	_	_	
10-64	1871-1876	viral	_	_	
10-65	1877-1885	pathogen	_	_	
10-66	1885-1886	.	_	_	

#Text=The flaviviruses consist of three clusters of antigenically related viruses: Dengue 1-4 (62-77% identity), Japanese, St.
11-1	1887-1890	The	_	_	
11-2	1891-1903	flaviviruses	_	_	
11-3	1904-1911	consist	_	_	
11-4	1912-1914	of	_	_	
11-5	1915-1920	three	_	_	
11-6	1921-1929	clusters	_	_	
11-7	1930-1932	of	_	_	
11-8	1933-1946	antigenically	_	_	
11-9	1947-1954	related	_	_	
11-10	1955-1962	viruses	_	_	
11-11	1962-1963	:	_	_	
11-12	1964-1970	Dengue	_	_	
11-13	1971-1972	1	_	_	
11-14	1972-1973	-	_	_	
11-15	1973-1974	4	_	_	
11-16	1975-1976	(	_	_	
11-17	1976-1978	62	_	_	
11-18	1978-1979	-	_	_	
11-19	1979-1982	77%	_	_	
11-20	1983-1991	identity	_	_	
11-21	1991-1992	)	_	_	
11-22	1992-1993	,	_	_	
11-23	1994-2002	Japanese	_	_	
11-24	2002-2003	,	_	_	
11-25	2004-2006	St	_	_	
11-26	2006-2007	.	_	_	

#Text=Louis and Murray Valley encephalitis viruses (75-82% identity), and the tick-borne encephalitis viruses (77-96% identity).
12-1	2008-2013	Louis	_	_	
12-2	2014-2017	and	_	_	
12-3	2018-2024	Murray	_	_	
12-4	2025-2031	Valley	_	_	
12-5	2032-2044	encephalitis	_	_	
12-6	2045-2052	viruses	_	_	
12-7	2053-2054	(	_	_	
12-8	2054-2056	75	_	_	
12-9	2056-2057	-	_	_	
12-10	2057-2060	82%	_	_	
12-11	2061-2069	identity	_	_	
12-12	2069-2070	)	_	_	
12-13	2070-2071	,	_	_	
12-14	2072-2075	and	_	_	
12-15	2076-2079	the	_	_	
12-16	2080-2090	tick-borne	_	_	
12-17	2091-2103	encephalitis	_	_	
12-18	2104-2111	viruses	_	_	
12-19	2112-2113	(	_	_	
12-20	2113-2115	77	_	_	
12-21	2115-2116	-	_	_	
12-22	2116-2119	96%	_	_	
12-23	2120-2128	identity	_	_	
12-24	2128-2129	)	_	_	
12-25	2129-2130	.	_	_	

#Text=Dengue virus can induce protective antibodies against SLE and Yellow fever (40-50% identity), but few efficient vaccines are available.
13-1	2131-2137	Dengue	_	_	
13-2	2138-2143	virus	_	_	
13-3	2144-2147	can	_	_	
13-4	2148-2154	induce	_	_	
13-5	2155-2165	protective	_	_	
13-6	2166-2176	antibodies	_	_	
13-7	2177-2184	against	_	_	
13-8	2185-2188	SLE	_	_	
13-9	2189-2192	and	_	_	
13-10	2193-2199	Yellow	_	_	
13-11	2200-2205	fever	_	_	
13-12	2206-2207	(	_	_	
13-13	2207-2209	40	_	_	
13-14	2209-2210	-	_	_	
13-15	2210-2213	50%	_	_	
13-16	2214-2222	identity	_	_	
13-17	2222-2223	)	_	_	
13-18	2223-2224	,	_	_	
13-19	2225-2228	but	_	_	
13-20	2229-2232	few	_	_	
13-21	2233-2242	efficient	_	_	
13-22	2243-2251	vaccines	_	_	
13-23	2252-2255	are	_	_	
13-24	2256-2265	available	_	_	
13-25	2265-2266	.	_	_	

#Text=To obtain genetic vaccines and recombinant polypeptides that exhibit enhanced cross-reactivity and immunogenicity, the polynucleotides that encode envelope proteins of related viruses are subjected to DNA shuffling.
14-1	2267-2269	To	_	_	
14-2	2270-2276	obtain	_	_	
14-3	2277-2284	genetic	_	_	
14-4	2285-2293	vaccines	_	_	
14-5	2294-2297	and	_	_	
14-6	2298-2309	recombinant	_	_	
14-7	2310-2322	polypeptides	_	_	
14-8	2323-2327	that	_	_	
14-9	2328-2335	exhibit	_	_	
14-10	2336-2344	enhanced	_	_	
14-11	2345-2361	cross-reactivity	_	_	
14-12	2362-2365	and	_	_	
14-13	2366-2380	immunogenicity	_	_	
14-14	2380-2381	,	_	_	
14-15	2382-2385	the	_	_	
14-16	2386-2401	polynucleotides	_	_	
14-17	2402-2406	that	_	_	
14-18	2407-2413	encode	_	_	
14-19	2414-2422	envelope	_	_	
14-20	2423-2431	proteins	_	_	
14-21	2432-2434	of	_	_	
14-22	2435-2442	related	_	_	
14-23	2443-2450	viruses	_	_	
14-24	2451-2454	are	_	_	
14-25	2455-2464	subjected	_	_	
14-26	2465-2467	to	_	_	
14-27	2468-2471	DNA	_	_	
14-28	2472-2481	shuffling	_	_	
14-29	2481-2482	.	_	_	

#Text=The resulting recombinant polynucleotides can be tested, either as genetic vaccines or by using the expressed polypeptides, for ability to induce a broadly reacting neutralizing antibody response.
15-1	2483-2486	The	_	_	
15-2	2487-2496	resulting	_	_	
15-3	2497-2508	recombinant	_	_	
15-4	2509-2524	polynucleotides	_	_	
15-5	2525-2528	can	_	_	
15-6	2529-2531	be	_	_	
15-7	2532-2538	tested	_	_	
15-8	2538-2539	,	_	_	
15-9	2540-2546	either	_	_	
15-10	2547-2549	as	_	_	
15-11	2550-2557	genetic	_	_	
15-12	2558-2566	vaccines	_	_	
15-13	2567-2569	or	_	_	
15-14	2570-2572	by	_	_	
15-15	2573-2578	using	_	_	
15-16	2579-2582	the	_	_	
15-17	2583-2592	expressed	_	_	
15-18	2593-2605	polypeptides	_	_	
15-19	2605-2606	,	_	_	
15-20	2607-2610	for	_	_	
15-21	2611-2618	ability	_	_	
15-22	2619-2621	to	_	_	
15-23	2622-2628	induce	_	_	
15-24	2629-2630	a	_	_	
15-25	2631-2638	broadly	_	_	
15-26	2639-2647	reacting	_	_	
15-27	2648-2660	neutralizing	_	_	
15-28	2661-2669	antibody	_	_	
15-29	2670-2678	response	_	_	
15-30	2678-2679	.	_	_	

#Text=Finally, those clones that are favorable in the preliminary screens can be tested for ability to protect a test animal against viral challenge.
#Text=[0099] Viral antigens that can be evolved by DNA shuffling for improved activity as vaccines include, but are not limited to, influenza A virus N2 neuraminidase (Kilbourne et al. (1995) Vaccine 13: 1799-1803); Dengue virus envelope (E) and premembrane (prM) antigens (Feighny et al. (1994) Am.
16-1	2680-2687	Finally	_	_	
16-2	2687-2688	,	_	_	
16-3	2689-2694	those	_	_	
16-4	2695-2701	clones	_	_	
16-5	2702-2706	that	_	_	
16-6	2707-2710	are	_	_	
16-7	2711-2720	favorable	_	_	
16-8	2721-2723	in	_	_	
16-9	2724-2727	the	_	_	
16-10	2728-2739	preliminary	_	_	
16-11	2740-2747	screens	_	_	
16-12	2748-2751	can	_	_	
16-13	2752-2754	be	_	_	
16-14	2755-2761	tested	_	_	
16-15	2762-2765	for	_	_	
16-16	2766-2773	ability	_	_	
16-17	2774-2776	to	_	_	
16-18	2777-2784	protect	_	_	
16-19	2785-2786	a	_	_	
16-20	2787-2791	test	_	_	
16-21	2792-2798	animal	_	_	
16-22	2799-2806	against	_	_	
16-23	2807-2812	viral	_	_	
16-24	2813-2822	challenge	_	_	
16-25	2822-2823	.	_	_	
16-26	2824-2825	[	_	_	
16-27	2825-2829	0099	_	_	
16-28	2829-2830	]	_	_	
16-29	2831-2836	Viral	_	_	
16-30	2837-2845	antigens	_	_	
16-31	2846-2850	that	_	_	
16-32	2851-2854	can	_	_	
16-33	2855-2857	be	_	_	
16-34	2858-2865	evolved	_	_	
16-35	2866-2868	by	_	_	
16-36	2869-2872	DNA	_	_	
16-37	2873-2882	shuffling	_	_	
16-38	2883-2886	for	_	_	
16-39	2887-2895	improved	_	_	
16-40	2896-2904	activity	_	_	
16-41	2905-2907	as	_	_	
16-42	2908-2916	vaccines	_	_	
16-43	2917-2924	include	_	_	
16-44	2924-2925	,	_	_	
16-45	2926-2929	but	_	_	
16-46	2930-2933	are	_	_	
16-47	2934-2937	not	_	_	
16-48	2938-2945	limited	_	_	
16-49	2946-2948	to	_	_	
16-50	2948-2949	,	_	_	
16-51	2950-2959	influenza	_	_	
16-52	2960-2961	A	_	_	
16-53	2962-2967	virus	_	_	
16-54	2968-2970	N2	_	_	
16-55	2971-2984	neuraminidase	_	_	
16-56	2985-2986	(	_	_	
16-57	2986-2995	Kilbourne	_	_	
16-58	2996-2998	et	_	_	
16-59	2999-3001	al	_	_	
16-60	3001-3002	.	_	_	
16-61	3003-3004	(	_	_	
16-62	3004-3008	1995	_	_	
16-63	3008-3009	)	_	_	
16-64	3010-3017	Vaccine	_	_	
16-65	3018-3020	13	_	_	
16-66	3020-3021	:	_	_	
16-67	3022-3026	1799	_	_	
16-68	3026-3027	-	_	_	
16-69	3027-3031	1803	_	_	
16-70	3031-3032	)	_	_	
16-71	3032-3033	;	_	_	
16-72	3034-3040	Dengue	_	_	
16-73	3041-3046	virus	_	_	
16-74	3047-3055	envelope	_	_	
16-75	3056-3057	(	_	_	
16-76	3057-3058	E	_	_	
16-77	3058-3059	)	_	_	
16-78	3060-3063	and	_	_	
16-79	3064-3075	premembrane	_	_	
16-80	3076-3077	(	_	_	
16-81	3077-3080	prM	_	_	
16-82	3080-3081	)	_	_	
16-83	3082-3090	antigens	_	_	
16-84	3091-3092	(	_	_	
16-85	3092-3099	Feighny	_	_	
16-86	3100-3102	et	_	_	
16-87	3103-3105	al	_	_	
16-88	3105-3106	.	_	_	
16-89	3107-3108	(	_	_	
16-90	3108-3112	1994	_	_	
16-91	3112-3113	)	_	_	
16-92	3114-3116	Am	_	_	
16-93	3116-3117	.	_	_	

#Text=J.
17-1	3118-3119	J	_	_	
17-2	3119-3120	.	_	_	

#Text=Trop.
18-1	3121-3125	Trop	_	_	
18-2	3125-3126	.	_	_	

#Text=Med.
19-1	3127-3130	Med	_	_	
19-2	3130-3131	.	_	_	

#Text=Hyg. 50: 322-328; Putnak et al. (1996) Am.
20-1	3132-3135	Hyg	_	_	
20-2	3135-3136	.	_	_	
20-3	3137-3139	50	_	_	
20-4	3139-3140	:	_	_	
20-5	3141-3144	322	_	_	
20-6	3144-3145	-	_	_	
20-7	3145-3148	328	_	_	
20-8	3148-3149	;	_	_	
20-9	3150-3156	Putnak	_	_	
20-10	3157-3159	et	_	_	
20-11	3160-3162	al	_	_	
20-12	3162-3163	.	_	_	
20-13	3164-3165	(	_	_	
20-14	3165-3169	1996	_	_	
20-15	3169-3170	)	_	_	
20-16	3171-3173	Am	_	_	
20-17	3173-3174	.	_	_	

#Text=J.
21-1	3175-3176	J	_	_	
21-2	3176-3177	.	_	_	

#Text=Trop.
22-1	3178-3182	Trop	_	_	
22-2	3182-3183	.	_	_	

#Text=Med.
23-1	3184-3187	Med	_	_	
23-2	3187-3188	.	_	_	

#Text=Hyg. 55: 504-10); HIV antigens Gag, Pol, Vif and Nef (Vogt et al. (1995) Vaccine 13: 202-208); HIV antigens gp120 and gp160 (Achour et al. (1995) Cell.
24-1	3189-3192	Hyg	_	_	
24-2	3192-3193	.	_	_	
24-3	3194-3196	55	_	_	
24-4	3196-3197	:	_	_	
24-5	3198-3201	504	_	_	
24-6	3201-3202	-	_	_	
24-7	3202-3204	10	_	_	
24-8	3204-3205	)	_	_	
24-9	3205-3206	;	_	_	
24-10	3207-3210	HIV	_	_	
24-11	3211-3219	antigens	_	_	
24-12	3220-3223	Gag	_	_	
24-13	3223-3224	,	_	_	
24-14	3225-3228	Pol	_	_	
24-15	3228-3229	,	_	_	
24-16	3230-3233	Vif	_	_	
24-17	3234-3237	and	_	_	
24-18	3238-3241	Nef	_	_	
24-19	3242-3243	(	_	_	
24-20	3243-3247	Vogt	_	_	
24-21	3248-3250	et	_	_	
24-22	3251-3253	al	_	_	
24-23	3253-3254	.	_	_	
24-24	3255-3256	(	_	_	
24-25	3256-3260	1995	_	_	
24-26	3260-3261	)	_	_	
24-27	3262-3269	Vaccine	_	_	
24-28	3270-3272	13	_	_	
24-29	3272-3273	:	_	_	
24-30	3274-3277	202	_	_	
24-31	3277-3278	-	_	_	
24-32	3278-3281	208	_	_	
24-33	3281-3282	)	_	_	
24-34	3282-3283	;	_	_	
24-35	3284-3287	HIV	_	_	
24-36	3288-3296	antigens	_	_	
24-37	3297-3302	gp120	_	_	
24-38	3303-3306	and	_	_	
24-39	3307-3312	gp160	_	_	
24-40	3313-3314	(	_	_	
24-41	3314-3320	Achour	_	_	
24-42	3321-3323	et	_	_	
24-43	3324-3326	al	_	_	
24-44	3326-3327	.	_	_	
24-45	3328-3329	(	_	_	
24-46	3329-3333	1995	_	_	
24-47	3333-3334	)	_	_	
24-48	3335-3339	Cell	_	_	
24-49	3339-3340	.	_	_	

#Text=Mol.
25-1	3341-3344	Mol	_	_	
25-2	3344-3345	.	_	_	

#Text=Biol. 41: 395-400; Hone et al. (1994) Dev.
26-1	3346-3350	Biol	_	_	
26-2	3350-3351	.	_	_	
26-3	3352-3354	41	_	_	
26-4	3354-3355	:	_	_	
26-5	3356-3359	395	_	_	
26-6	3359-3360	-	_	_	
26-7	3360-3363	400	_	_	
26-8	3363-3364	;	_	_	
26-9	3365-3369	Hone	_	_	
26-10	3370-3372	et	_	_	
26-11	3373-3375	al	_	_	
26-12	3375-3376	.	_	_	
26-13	3377-3378	(	_	_	
26-14	3378-3382	1994	_	_	
26-15	3382-3383	)	_	_	
26-16	3384-3387	Dev	_	_	
26-17	3387-3388	.	_	_	

#Text=Biol.
27-1	3389-3393	Biol	_	_	
27-2	3393-3394	.	_	_	

#Text=Stand. 82: 159-162); gp41 epitope of human immunodeficiency virus (Eckhart et al. (1996) J.
28-1	3395-3400	Stand	_	_	
28-2	3400-3401	.	_	_	
28-3	3402-3404	82	_	_	
28-4	3404-3405	:	_	_	
28-5	3406-3409	159	_	_	
28-6	3409-3410	-	_	_	
28-7	3410-3413	162	_	_	
28-8	3413-3414	)	_	_	
28-9	3414-3415	;	_	_	
28-10	3416-3420	gp41	_	_	
28-11	3421-3428	epitope	_	_	
28-12	3429-3431	of	_	_	
28-13	3432-3437	human	_	_	
28-14	3438-3454	immunodeficiency	_	_	
28-15	3455-3460	virus	_	_	
28-16	3461-3462	(	_	_	
28-17	3462-3469	Eckhart	_	_	
28-18	3470-3472	et	_	_	
28-19	3473-3475	al	_	_	
28-20	3475-3476	.	_	_	
28-21	3477-3478	(	_	_	
28-22	3478-3482	1996	_	_	
28-23	3482-3483	)	_	_	
28-24	3484-3485	J	_	_	
28-25	3485-3486	.	_	_	

#Text=Gen.
29-1	3487-3490	Gen	_	_	
29-2	3490-3491	.	_	_	

#Text=Virol. 77: 2001-2008); rotavirus antigen VP4 (Mattion et al. (1995) J.
30-1	3492-3497	Virol	_	_	
30-2	3497-3498	.	_	_	
30-3	3499-3501	77	_	_	
30-4	3501-3502	:	_	_	
30-5	3503-3507	2001	_	_	
30-6	3507-3508	-	_	_	
30-7	3508-3512	2008	_	_	
30-8	3512-3513	)	_	_	
30-9	3513-3514	;	_	_	
30-10	3515-3524	rotavirus	_	_	
30-11	3525-3532	antigen	_	_	
30-12	3533-3536	VP4	_	_	
30-13	3537-3538	(	_	_	
30-14	3538-3545	Mattion	_	_	
30-15	3546-3548	et	_	_	
30-16	3549-3551	al	_	_	
30-17	3551-3552	.	_	_	
30-18	3553-3554	(	_	_	
30-19	3554-3558	1995	_	_	
30-20	3558-3559	)	_	_	
30-21	3560-3561	J	_	_	
30-22	3561-3562	.	_	_	

#Text=Virol. 69: 5132-5137); the rotavirus protein VP7 or VP7sc (Emslie et al. (1995) J.
31-1	3563-3568	Virol	_	_	
31-2	3568-3569	.	_	_	
31-3	3570-3572	69	_	_	
31-4	3572-3573	:	_	_	
31-5	3574-3578	5132	_	_	
31-6	3578-3579	-	_	_	
31-7	3579-3583	5137	_	_	
31-8	3583-3584	)	_	_	
31-9	3584-3585	;	_	_	
31-10	3586-3589	the	_	_	
31-11	3590-3599	rotavirus	_	_	
31-12	3600-3607	protein	_	_	
31-13	3608-3611	VP7	_	_	
31-14	3612-3614	or	_	_	
31-15	3615-3620	VP7sc	_	_	
31-16	3621-3622	(	_	_	
31-17	3622-3628	Emslie	_	_	
31-18	3629-3631	et	_	_	
31-19	3632-3634	al	_	_	
31-20	3634-3635	.	_	_	
31-21	3636-3637	(	_	_	
31-22	3637-3641	1995	_	_	
31-23	3641-3642	)	_	_	
31-24	3643-3644	J	_	_	
31-25	3644-3645	.	_	_	

#Text=Virol. 69: 1747-1754; Xu et al. (1995) J.
32-1	3646-3651	Virol	_	_	
32-2	3651-3652	.	_	_	
32-3	3653-3655	69	_	_	
32-4	3655-3656	:	_	_	
32-5	3657-3661	1747	_	_	
32-6	3661-3662	-	_	_	
32-7	3662-3666	1754	_	_	
32-8	3666-3667	;	_	_	
32-9	3668-3670	Xu	_	_	
32-10	3671-3673	et	_	_	
32-11	3674-3676	al	_	_	
32-12	3676-3677	.	_	_	
32-13	3678-3679	(	_	_	
32-14	3679-3683	1995	_	_	
32-15	3683-3684	)	_	_	
32-16	3685-3686	J	_	_	
32-17	3686-3687	.	_	_	

#Text=Gen.
33-1	3688-3691	Gen	_	_	
33-2	3691-3692	.	_	_	

#Text=Virol. 76: 1971-1980); herpes simplex virus (HSV) glycoproteins gB, gC, gD, gE, gG, gH, and gI (Fleck et al. (1994) Med.
34-1	3693-3698	Virol	_	_	
34-2	3698-3699	.	_	_	
34-3	3700-3702	76	_	_	
34-4	3702-3703	:	_	_	
34-5	3704-3708	1971	_	_	
34-6	3708-3709	-	_	_	
34-7	3709-3713	1980	_	_	
34-8	3713-3714	)	_	_	
34-9	3714-3715	;	_	_	
34-10	3716-3722	herpes	_	_	
34-11	3723-3730	simplex	_	_	
34-12	3731-3736	virus	_	_	
34-13	3737-3738	(	_	_	
34-14	3738-3741	HSV	_	_	
34-15	3741-3742	)	_	_	
34-16	3743-3756	glycoproteins	_	_	
34-17	3757-3759	gB	_	_	
34-18	3759-3760	,	_	_	
34-19	3761-3763	gC	_	_	
34-20	3763-3764	,	_	_	
34-21	3765-3767	gD	_	_	
34-22	3767-3768	,	_	_	
34-23	3769-3771	gE	_	_	
34-24	3771-3772	,	_	_	
34-25	3773-3775	gG	_	_	
34-26	3775-3776	,	_	_	
34-27	3777-3779	gH	_	_	
34-28	3779-3780	,	_	_	
34-29	3781-3784	and	_	_	
34-30	3785-3787	gI	_	_	
34-31	3788-3789	(	_	_	
34-32	3789-3794	Fleck	_	_	
34-33	3795-3797	et	_	_	
34-34	3798-3800	al	_	_	
34-35	3800-3801	.	_	_	
34-36	3802-3803	(	_	_	
34-37	3803-3807	1994	_	_	
34-38	3807-3808	)	_	_	
34-39	3809-3812	Med	_	_	
34-40	3812-3813	.	_	_	

#Text=Microbiol.
35-1	3814-3823	Microbiol	_	_	
35-2	3823-3824	.	_	_	

#Text=Immunol.
36-1	3825-3832	Immunol	_	_	
36-2	3832-3833	.	_	_	

#Text=(Berl) 183: 87-94 [Mattion, 1995]; Ghiasi et al. (1995) Invest.
37-1	3834-3835	(	_	_	
37-2	3835-3839	Berl	_	_	
37-3	3839-3840	)	_	_	
37-4	3841-3844	183	_	_	
37-5	3844-3845	:	_	_	
37-6	3846-3848	87	_	_	
37-7	3848-3849	-	_	_	
37-8	3849-3851	94	_	_	
37-9	3852-3853	[	_	_	
37-10	3853-3860	Mattion	_	_	
37-11	3860-3861	,	_	_	
37-12	3862-3866	1995	_	_	
37-13	3866-3867	]	_	_	
37-14	3867-3868	;	_	_	
37-15	3869-3875	Ghiasi	_	_	
37-16	3876-3878	et	_	_	
37-17	3879-3881	al	_	_	
37-18	3881-3882	.	_	_	
37-19	3883-3884	(	_	_	
37-20	3884-3888	1995	_	_	
37-21	3888-3889	)	_	_	
37-22	3890-3896	Invest	_	_	
37-23	3896-3897	.	_	_	

#Text=Ophthalmol.
38-1	3898-3908	Ophthalmol	_	_	
38-2	3908-3909	.	_	_	

#Text=Vis.
39-1	3910-3913	Vis	_	_	
39-2	3913-3914	.	_	_	

#Text=Sci. 36: 1352-1360; McLean et al. (1994) J.
40-1	3915-3918	Sci	_	_	
40-2	3918-3919	.	_	_	
40-3	3920-3922	36	_	_	
40-4	3922-3923	:	_	_	
40-5	3924-3928	1352	_	_	
40-6	3928-3929	-	_	_	
40-7	3929-3933	1360	_	_	
40-8	3933-3934	;	_	_	
40-9	3935-3941	McLean	_	_	
40-10	3942-3944	et	_	_	
40-11	3945-3947	al	_	_	
40-12	3947-3948	.	_	_	
40-13	3949-3950	(	_	_	
40-14	3950-3954	1994	_	_	
40-15	3954-3955	)	_	_	
40-16	3956-3957	J	_	_	
40-17	3957-3958	.	_	_	

#Text=Infect.
41-1	3959-3965	Infect	_	_	
41-2	3965-3966	.	_	_	

#Text=Dis. 170: 1100-1109); immediate-early protein ICP47 of herpes simplex virus-type 1 (HSV-1) (Banks et al. (1994) Virology 200: 236-245); immediate-early (IE) proteins ICP27, ICP0, and ICP4 of herpes simplex virus (Manickan et al. (1995) J.
42-1	3967-3970	Dis	_	_	
42-2	3970-3971	.	_	_	
42-3	3972-3975	170	_	_	
42-4	3975-3976	:	_	_	
42-5	3977-3981	1100	_	_	
42-6	3981-3982	-	_	_	
42-7	3982-3986	1109	_	_	
42-8	3986-3987	)	_	_	
42-9	3987-3988	;	_	_	
42-10	3989-4004	immediate-early	_	_	
42-11	4005-4012	protein	_	_	
42-12	4013-4018	ICP47	_	_	
42-13	4019-4021	of	_	_	
42-14	4022-4028	herpes	_	_	
42-15	4029-4036	simplex	_	_	
42-16	4037-4047	virus-type	_	_	
42-17	4048-4049	1	_	_	
42-18	4050-4051	(	_	_	
42-19	4051-4054	HSV	_	_	
42-20	4054-4055	-	_	_	
42-21	4055-4056	1	_	_	
42-22	4056-4057	)	_	_	
42-23	4058-4059	(	_	_	
42-24	4059-4064	Banks	_	_	
42-25	4065-4067	et	_	_	
42-26	4068-4070	al	_	_	
42-27	4070-4071	.	_	_	
42-28	4072-4073	(	_	_	
42-29	4073-4077	1994	_	_	
42-30	4077-4078	)	_	_	
42-31	4079-4087	Virology	_	_	
42-32	4088-4091	200	_	_	
42-33	4091-4092	:	_	_	
42-34	4093-4096	236	_	_	
42-35	4096-4097	-	_	_	
42-36	4097-4100	245	_	_	
42-37	4100-4101	)	_	_	
42-38	4101-4102	;	_	_	
42-39	4103-4118	immediate-early	_	_	
42-40	4119-4120	(	_	_	
42-41	4120-4122	IE	_	_	
42-42	4122-4123	)	_	_	
42-43	4124-4132	proteins	_	_	
42-44	4133-4138	ICP27	_	_	
42-45	4138-4139	,	_	_	
42-46	4140-4144	ICP0	_	_	
42-47	4144-4145	,	_	_	
42-48	4146-4149	and	_	_	
42-49	4150-4154	ICP4	_	_	
42-50	4155-4157	of	_	_	
42-51	4158-4164	herpes	_	_	
42-52	4165-4172	simplex	_	_	
42-53	4173-4178	virus	_	_	
42-54	4179-4180	(	_	_	
42-55	4180-4188	Manickan	_	_	
42-56	4189-4191	et	_	_	
42-57	4192-4194	al	_	_	
42-58	4194-4195	.	_	_	
42-59	4196-4197	(	_	_	
42-60	4197-4201	1995	_	_	
42-61	4201-4202	)	_	_	
42-62	4203-4204	J	_	_	
42-63	4204-4205	.	_	_	

#Text=Virol. 69: 4711-4716); influenza virus nucleoprotein and hemagglutinin (Deck et al. (1997) Vaccine 15: 71-78; Fu et al. (1997) J.
43-1	4206-4211	Virol	_	_	
43-2	4211-4212	.	_	_	
43-3	4213-4215	69	_	_	
43-4	4215-4216	:	_	_	
43-5	4217-4221	4711	_	_	
43-6	4221-4222	-	_	_	
43-7	4222-4226	4716	_	_	
43-8	4226-4227	)	_	_	
43-9	4227-4228	;	_	_	
43-10	4229-4238	influenza	_	_	
43-11	4239-4244	virus	_	_	
43-12	4245-4258	nucleoprotein	_	_	
43-13	4259-4262	and	_	_	
43-14	4263-4276	hemagglutinin	_	_	
43-15	4277-4278	(	_	_	
43-16	4278-4282	Deck	_	_	
43-17	4283-4285	et	_	_	
43-18	4286-4288	al	_	_	
43-19	4288-4289	.	_	_	
43-20	4290-4291	(	_	_	
43-21	4291-4295	1997	_	_	
43-22	4295-4296	)	_	_	
43-23	4297-4304	Vaccine	_	_	
43-24	4305-4307	15	_	_	
43-25	4307-4308	:	_	_	
43-26	4309-4311	71	_	_	
43-27	4311-4312	-	_	_	
43-28	4312-4314	78	_	_	
43-29	4314-4315	;	_	_	
43-30	4316-4318	Fu	_	_	
43-31	4319-4321	et	_	_	
43-32	4322-4324	al	_	_	
43-33	4324-4325	.	_	_	
43-34	4326-4327	(	_	_	
43-35	4327-4331	1997	_	_	
43-36	4331-4332	)	_	_	
43-37	4333-4334	J	_	_	
43-38	4334-4335	.	_	_	

#Text=Virol. 71: 2715-2721); B19 parvovirus capsid proteins VP1 (Kawase et al. (1995) Virology 211: 359-366) or VP2 (Brown et al. (1994) Virology 198: 477-488); Hepatitis B virus core and e antigen (Schodel et al. (1996) Intervirology 39: 104-106); hepatitis B surface antigen (Shiau and Murray (1997) J.
44-1	4336-4341	Virol	_	_	
44-2	4341-4342	.	_	_	
44-3	4343-4345	71	_	_	
44-4	4345-4346	:	_	_	
44-5	4347-4351	2715	_	_	
44-6	4351-4352	-	_	_	
44-7	4352-4356	2721	_	_	
44-8	4356-4357	)	_	_	
44-9	4357-4358	;	_	_	
44-10	4359-4362	B19	_	_	
44-11	4363-4373	parvovirus	_	_	
44-12	4374-4380	capsid	_	_	
44-13	4381-4389	proteins	_	_	
44-14	4390-4393	VP1	_	_	
44-15	4394-4395	(	_	_	
44-16	4395-4401	Kawase	_	_	
44-17	4402-4404	et	_	_	
44-18	4405-4407	al	_	_	
44-19	4407-4408	.	_	_	
44-20	4409-4410	(	_	_	
44-21	4410-4414	1995	_	_	
44-22	4414-4415	)	_	_	
44-23	4416-4424	Virology	_	_	
44-24	4425-4428	211	_	_	
44-25	4428-4429	:	_	_	
44-26	4430-4433	359	_	_	
44-27	4433-4434	-	_	_	
44-28	4434-4437	366	_	_	
44-29	4437-4438	)	_	_	
44-30	4439-4441	or	_	_	
44-31	4442-4445	VP2	_	_	
44-32	4446-4447	(	_	_	
44-33	4447-4452	Brown	_	_	
44-34	4453-4455	et	_	_	
44-35	4456-4458	al	_	_	
44-36	4458-4459	.	_	_	
44-37	4460-4461	(	_	_	
44-38	4461-4465	1994	_	_	
44-39	4465-4466	)	_	_	
44-40	4467-4475	Virology	_	_	
44-41	4476-4479	198	_	_	
44-42	4479-4480	:	_	_	
44-43	4481-4484	477	_	_	
44-44	4484-4485	-	_	_	
44-45	4485-4488	488	_	_	
44-46	4488-4489	)	_	_	
44-47	4489-4490	;	_	_	
44-48	4491-4500	Hepatitis	_	_	
44-49	4501-4502	B	_	_	
44-50	4503-4508	virus	_	_	
44-51	4509-4513	core	_	_	
44-52	4514-4517	and	_	_	
44-53	4518-4519	e	_	_	
44-54	4520-4527	antigen	_	_	
44-55	4528-4529	(	_	_	
44-56	4529-4536	Schodel	_	_	
44-57	4537-4539	et	_	_	
44-58	4540-4542	al	_	_	
44-59	4542-4543	.	_	_	
44-60	4544-4545	(	_	_	
44-61	4545-4549	1996	_	_	
44-62	4549-4550	)	_	_	
44-63	4551-4564	Intervirology	_	_	
44-64	4565-4567	39	_	_	
44-65	4567-4568	:	_	_	
44-66	4569-4572	104	_	_	
44-67	4572-4573	-	_	_	
44-68	4573-4576	106	_	_	
44-69	4576-4577	)	_	_	
44-70	4577-4578	;	_	_	
44-71	4579-4588	hepatitis	_	_	
44-72	4589-4590	B	_	_	
44-73	4591-4598	surface	_	_	
44-74	4599-4606	antigen	_	_	
44-75	4607-4608	(	_	_	
44-76	4608-4613	Shiau	_	_	
44-77	4614-4617	and	_	_	
44-78	4618-4624	Murray	_	_	
44-79	4625-4626	(	_	_	
44-80	4626-4630	1997	_	_	
44-81	4630-4631	)	_	_	
44-82	4632-4633	J	_	_	
44-83	4633-4634	.	_	_	

#Text=Med.
45-1	4635-4638	Med	_	_	
45-2	4638-4639	.	_	_	

#Text=Virol. 51: 159-166); hepatitis B surface antigen fused to the core antigen of the virus (Id.); Hepatitis B virus core-preS2 particles (Nemeckova et al. (1996) Acta Virol. 40: 273-279); HBV preS2-S protein (Kutinova et al. (1996) Vaccine 14: 1045-1052); VZV glycoprotein I (Kutinova et al. (1996) Vaccine 14: 1045-1052); rabies virus glycoproteins (Xiang et al. (1994) Virology 199: 132-140; Xuan et al. (1995) Virus Res. 36: 151-161) or ribonucleocapsid (Hooper et al. (1994) Proc.
46-1	4640-4645	Virol	_	_	
46-2	4645-4646	.	_	_	
46-3	4647-4649	51	_	_	
46-4	4649-4650	:	_	_	
46-5	4651-4654	159	_	_	
46-6	4654-4655	-	_	_	
46-7	4655-4658	166	_	_	
46-8	4658-4659	)	_	_	
46-9	4659-4660	;	_	_	
46-10	4661-4670	hepatitis	_	_	
46-11	4671-4672	B	_	_	
46-12	4673-4680	surface	_	_	
46-13	4681-4688	antigen	_	_	
46-14	4689-4694	fused	_	_	
46-15	4695-4697	to	_	_	
46-16	4698-4701	the	_	_	
46-17	4702-4706	core	_	_	
46-18	4707-4714	antigen	_	_	
46-19	4715-4717	of	_	_	
46-20	4718-4721	the	_	_	
46-21	4722-4727	virus	_	_	
46-22	4728-4729	(	_	_	
46-23	4729-4731	Id	_	_	
46-24	4731-4732	.	_	_	
46-25	4732-4733	)	_	_	
46-26	4733-4734	;	_	_	
46-27	4735-4744	Hepatitis	_	_	
46-28	4745-4746	B	_	_	
46-29	4747-4752	virus	_	_	
46-30	4753-4763	core-preS2	_	_	
46-31	4764-4773	particles	_	_	
46-32	4774-4775	(	_	_	
46-33	4775-4784	Nemeckova	_	_	
46-34	4785-4787	et	_	_	
46-35	4788-4790	al	_	_	
46-36	4790-4791	.	_	_	
46-37	4792-4793	(	_	_	
46-38	4793-4797	1996	_	_	
46-39	4797-4798	)	_	_	
46-40	4799-4803	Acta	_	_	
46-41	4804-4809	Virol	_	_	
46-42	4809-4810	.	_	_	
46-43	4811-4813	40	_	_	
46-44	4813-4814	:	_	_	
46-45	4815-4818	273	_	_	
46-46	4818-4819	-	_	_	
46-47	4819-4822	279	_	_	
46-48	4822-4823	)	_	_	
46-49	4823-4824	;	_	_	
46-50	4825-4828	HBV	_	_	
46-51	4829-4834	preS2	_	_	
46-52	4834-4835	-	_	_	
46-53	4835-4836	S	_	_	
46-54	4837-4844	protein	_	_	
46-55	4845-4846	(	_	_	
46-56	4846-4854	Kutinova	_	_	
46-57	4855-4857	et	_	_	
46-58	4858-4860	al	_	_	
46-59	4860-4861	.	_	_	
46-60	4862-4863	(	_	_	
46-61	4863-4867	1996	_	_	
46-62	4867-4868	)	_	_	
46-63	4869-4876	Vaccine	_	_	
46-64	4877-4879	14	_	_	
46-65	4879-4880	:	_	_	
46-66	4881-4885	1045	_	_	
46-67	4885-4886	-	_	_	
46-68	4886-4890	1052	_	_	
46-69	4890-4891	)	_	_	
46-70	4891-4892	;	_	_	
46-71	4893-4896	VZV	_	_	
46-72	4897-4909	glycoprotein	_	_	
46-73	4910-4911	I	_	_	
46-74	4912-4913	(	_	_	
46-75	4913-4921	Kutinova	_	_	
46-76	4922-4924	et	_	_	
46-77	4925-4927	al	_	_	
46-78	4927-4928	.	_	_	
46-79	4929-4930	(	_	_	
46-80	4930-4934	1996	_	_	
46-81	4934-4935	)	_	_	
46-82	4936-4943	Vaccine	_	_	
46-83	4944-4946	14	_	_	
46-84	4946-4947	:	_	_	
46-85	4948-4952	1045	_	_	
46-86	4952-4953	-	_	_	
46-87	4953-4957	1052	_	_	
46-88	4957-4958	)	_	_	
46-89	4958-4959	;	_	_	
46-90	4960-4966	rabies	_	_	
46-91	4967-4972	virus	_	_	
46-92	4973-4986	glycoproteins	_	_	
46-93	4987-4988	(	_	_	
46-94	4988-4993	Xiang	_	_	
46-95	4994-4996	et	_	_	
46-96	4997-4999	al	_	_	
46-97	4999-5000	.	_	_	
46-98	5001-5002	(	_	_	
46-99	5002-5006	1994	_	_	
46-100	5006-5007	)	_	_	
46-101	5008-5016	Virology	_	_	
46-102	5017-5020	199	_	_	
46-103	5020-5021	:	_	_	
46-104	5022-5025	132	_	_	
46-105	5025-5026	-	_	_	
46-106	5026-5029	140	_	_	
46-107	5029-5030	;	_	_	
46-108	5031-5035	Xuan	_	_	
46-109	5036-5038	et	_	_	
46-110	5039-5041	al	_	_	
46-111	5041-5042	.	_	_	
46-112	5043-5044	(	_	_	
46-113	5044-5048	1995	_	_	
46-114	5048-5049	)	_	_	
46-115	5050-5055	Virus	_	_	
46-116	5056-5059	Res	_	_	
46-117	5059-5060	.	_	_	
46-118	5061-5063	36	_	_	
46-119	5063-5064	:	_	_	
46-120	5065-5068	151	_	_	
46-121	5068-5069	-	_	_	
46-122	5069-5072	161	_	_	
46-123	5072-5073	)	_	_	
46-124	5074-5076	or	_	_	
46-125	5077-5093	ribonucleocapsid	_	_	
46-126	5094-5095	(	_	_	
46-127	5095-5101	Hooper	_	_	
46-128	5102-5104	et	_	_	
46-129	5105-5107	al	_	_	
46-130	5107-5108	.	_	_	
46-131	5109-5110	(	_	_	
46-132	5110-5114	1994	_	_	
46-133	5114-5115	)	_	_	
46-134	5116-5120	Proc	_	_	
46-135	5120-5121	.	_	_	

#Text=Nat'l.
47-1	5122-5127	Nat'l	_	_	
47-2	5127-5128	.	_	_	

#Text=Acad.
48-1	5129-5133	Acad	_	_	
48-2	5133-5134	.	_	_	

#Text=Sci.
49-1	5135-5138	Sci	_	_	
49-2	5138-5139	.	_	_	

#Text=USA 91: 10908-10912); human cytomegalovirus (HCMV) glycoprotein B (UL55) (Britt et al. (1995) J.
50-1	5140-5143	USA	_	_	
50-2	5144-5146	91	_	_	
50-3	5146-5147	:	_	_	
50-4	5148-5153	10908	_	_	
50-5	5153-5154	-	_	_	
50-6	5154-5159	10912	_	_	
50-7	5159-5160	)	_	_	
50-8	5160-5161	;	_	_	
50-9	5162-5167	human	_	_	
50-10	5168-5183	cytomegalovirus	_	_	
50-11	5184-5185	(	_	_	
50-12	5185-5189	HCMV	_	_	
50-13	5189-5190	)	_	_	
50-14	5191-5203	glycoprotein	_	_	
50-15	5204-5205	B	_	_	
50-16	5206-5207	(	_	_	
50-17	5207-5211	UL55	_	_	
50-18	5211-5212	)	_	_	
50-19	5213-5214	(	_	_	
50-20	5214-5219	Britt	_	_	
50-21	5220-5222	et	_	_	
50-22	5223-5225	al	_	_	
50-23	5225-5226	.	_	_	
50-24	5227-5228	(	_	_	
50-25	5228-5232	1995	_	_	
50-26	5232-5233	)	_	_	
50-27	5234-5235	J	_	_	
50-28	5235-5236	.	_	_	

#Text=Infect.
51-1	5237-5243	Infect	_	_	
51-2	5243-5244	.	_	_	

#Text=Dis. 171: 18-25); the hepatitis C virus (HCV) nucleocapsid protein in a secreted or a nonsecreted form, or as a fusion protein with the middle (pre-S2 and S) or major (S) surface antigens of hepatitis B virus (HBV) (Inchauspe et al. (1997) DNA Cell Biol. 16: 185-195; Major et al. (1995) J.
52-1	5245-5248	Dis	_	_	
52-2	5248-5249	.	_	_	
52-3	5250-5253	171	_	_	
52-4	5253-5254	:	_	_	
52-5	5255-5257	18	_	_	
52-6	5257-5258	-	_	_	
52-7	5258-5260	25	_	_	
52-8	5260-5261	)	_	_	
52-9	5261-5262	;	_	_	
52-10	5263-5266	the	_	_	
52-11	5267-5276	hepatitis	_	_	
52-12	5277-5278	C	_	_	
52-13	5279-5284	virus	_	_	
52-14	5285-5286	(	_	_	
52-15	5286-5289	HCV	_	_	
52-16	5289-5290	)	_	_	
52-17	5291-5303	nucleocapsid	_	_	
52-18	5304-5311	protein	_	_	
52-19	5312-5314	in	_	_	
52-20	5315-5316	a	_	_	
52-21	5317-5325	secreted	_	_	
52-22	5326-5328	or	_	_	
52-23	5329-5330	a	_	_	
52-24	5331-5342	nonsecreted	_	_	
52-25	5343-5347	form	_	_	
52-26	5347-5348	,	_	_	
52-27	5349-5351	or	_	_	
52-28	5352-5354	as	_	_	
52-29	5355-5356	a	_	_	
52-30	5357-5363	fusion	_	_	
52-31	5364-5371	protein	_	_	
52-32	5372-5376	with	_	_	
52-33	5377-5380	the	_	_	
52-34	5381-5387	middle	_	_	
52-35	5388-5389	(	_	_	
52-36	5389-5395	pre-S2	_	_	
52-37	5396-5399	and	_	_	
52-38	5400-5401	S	_	_	
52-39	5401-5402	)	_	_	
52-40	5403-5405	or	_	_	
52-41	5406-5411	major	_	_	
52-42	5412-5413	(	_	_	
52-43	5413-5414	S	_	_	
52-44	5414-5415	)	_	_	
52-45	5416-5423	surface	_	_	
52-46	5424-5432	antigens	_	_	
52-47	5433-5435	of	_	_	
52-48	5436-5445	hepatitis	_	_	
52-49	5446-5447	B	_	_	
52-50	5448-5453	virus	_	_	
52-51	5454-5455	(	_	_	
52-52	5455-5458	HBV	_	_	
52-53	5458-5459	)	_	_	
52-54	5460-5461	(	_	_	
52-55	5461-5470	Inchauspe	_	_	
52-56	5471-5473	et	_	_	
52-57	5474-5476	al	_	_	
52-58	5476-5477	.	_	_	
52-59	5478-5479	(	_	_	
52-60	5479-5483	1997	_	_	
52-61	5483-5484	)	_	_	
52-62	5485-5488	DNA	_	_	
52-63	5489-5493	Cell	_	_	
52-64	5494-5498	Biol	_	_	
52-65	5498-5499	.	_	_	
52-66	5500-5502	16	_	_	
52-67	5502-5503	:	_	_	
52-68	5504-5507	185	_	_	
52-69	5507-5508	-	_	_	
52-70	5508-5511	195	_	_	
52-71	5511-5512	;	_	_	
52-72	5513-5518	Major	_	_	
52-73	5519-5521	et	_	_	
52-74	5522-5524	al	_	_	
52-75	5524-5525	.	_	_	
52-76	5526-5527	(	_	_	
52-77	5527-5531	1995	_	_	
52-78	5531-5532	)	_	_	
52-79	5533-5534	J	_	_	
52-80	5534-5535	.	_	_	

#Text=Virol. 69: 5798-5805); the hepatitis C virus antigens: the core protein (pC); E1 (pE1) and E2 (pE2) alone or as fusion proteins (Saito et al. (1997) Gastroenterology 112: 1321-1330); the gene encoding respiratory syncytial virus fusion protein (PFP-2) (Falsey and Walsh (1996) Vaccine 14: 1214-1218; Piedra et al. (1996) Pediatr.
53-1	5536-5541	Virol	_	_	
53-2	5541-5542	.	_	_	
53-3	5543-5545	69	_	_	
53-4	5545-5546	:	_	_	
53-5	5547-5551	5798	_	_	
53-6	5551-5552	-	_	_	
53-7	5552-5556	5805	_	_	
53-8	5556-5557	)	_	_	
53-9	5557-5558	;	_	_	
53-10	5559-5562	the	_	_	
53-11	5563-5572	hepatitis	_	_	
53-12	5573-5574	C	_	_	
53-13	5575-5580	virus	_	_	
53-14	5581-5589	antigens	_	_	
53-15	5589-5590	:	_	_	
53-16	5591-5594	the	_	_	
53-17	5595-5599	core	_	_	
53-18	5600-5607	protein	_	_	
53-19	5608-5609	(	_	_	
53-20	5609-5611	pC	_	_	
53-21	5611-5612	)	_	_	
53-22	5612-5613	;	_	_	
53-23	5614-5616	E1	_	_	
53-24	5617-5618	(	_	_	
53-25	5618-5621	pE1	_	_	
53-26	5621-5622	)	_	_	
53-27	5623-5626	and	_	_	
53-28	5627-5629	E2	_	_	
53-29	5630-5631	(	_	_	
53-30	5631-5634	pE2	_	_	
53-31	5634-5635	)	_	_	
53-32	5636-5641	alone	_	_	
53-33	5642-5644	or	_	_	
53-34	5645-5647	as	_	_	
53-35	5648-5654	fusion	_	_	
53-36	5655-5663	proteins	_	_	
53-37	5664-5665	(	_	_	
53-38	5665-5670	Saito	_	_	
53-39	5671-5673	et	_	_	
53-40	5674-5676	al	_	_	
53-41	5676-5677	.	_	_	
53-42	5678-5679	(	_	_	
53-43	5679-5683	1997	_	_	
53-44	5683-5684	)	_	_	
53-45	5685-5701	Gastroenterology	_	_	
53-46	5702-5705	112	_	_	
53-47	5705-5706	:	_	_	
53-48	5707-5711	1321	_	_	
53-49	5711-5712	-	_	_	
53-50	5712-5716	1330	_	_	
53-51	5716-5717	)	_	_	
53-52	5717-5718	;	_	_	
53-53	5719-5722	the	_	_	
53-54	5723-5727	gene	_	_	
53-55	5728-5736	encoding	_	_	
53-56	5737-5748	respiratory	_	_	
53-57	5749-5758	syncytial	_	_	
53-58	5759-5764	virus	_	_	
53-59	5765-5771	fusion	_	_	
53-60	5772-5779	protein	_	_	
53-61	5780-5781	(	_	_	
53-62	5781-5784	PFP	_	_	
53-63	5784-5785	-	_	_	
53-64	5785-5786	2	_	_	
53-65	5786-5787	)	_	_	
53-66	5788-5789	(	_	_	
53-67	5789-5795	Falsey	_	_	
53-68	5796-5799	and	_	_	
53-69	5800-5805	Walsh	_	_	
53-70	5806-5807	(	_	_	
53-71	5807-5811	1996	_	_	
53-72	5811-5812	)	_	_	
53-73	5813-5820	Vaccine	_	_	
53-74	5821-5823	14	_	_	
53-75	5823-5824	:	_	_	
53-76	5825-5829	1214	_	_	
53-77	5829-5830	-	_	_	
53-78	5830-5834	1218	_	_	
53-79	5834-5835	;	_	_	
53-80	5836-5842	Piedra	_	_	
53-81	5843-5845	et	_	_	
53-82	5846-5848	al	_	_	
53-83	5848-5849	.	_	_	
53-84	5850-5851	(	_	_	
53-85	5851-5855	1996	_	_	
53-86	5855-5856	)	_	_	
53-87	5857-5864	Pediatr	_	_	
53-88	5864-5865	.	_	_	

#Text=Infect.
54-1	5866-5872	Infect	_	_	
54-2	5872-5873	.	_	_	

#Text=Dis.
55-1	5874-5877	Dis	_	_	
55-2	5877-5878	.	_	_	

#Text=J. 15: 23-31); the VP6 and VP7 genes of rotaviruses (Choi et al. (1997) Virology 232: 129-138; Jin et al. (1996) Arch.
56-1	5879-5880	J	_	_	
56-2	5880-5881	.	_	_	
56-3	5882-5884	15	_	_	
56-4	5884-5885	:	_	_	
56-5	5886-5888	23	_	_	
56-6	5888-5889	-	_	_	
56-7	5889-5891	31	_	_	
56-8	5891-5892	)	_	_	
56-9	5892-5893	;	_	_	
56-10	5894-5897	the	_	_	
56-11	5898-5901	VP6	_	_	
56-12	5902-5905	and	_	_	
56-13	5906-5909	VP7	_	_	
56-14	5910-5915	genes	_	_	
56-15	5916-5918	of	_	_	
56-16	5919-5930	rotaviruses	_	_	
56-17	5931-5932	(	_	_	
56-18	5932-5936	Choi	_	_	
56-19	5937-5939	et	_	_	
56-20	5940-5942	al	_	_	
56-21	5942-5943	.	_	_	
56-22	5944-5945	(	_	_	
56-23	5945-5949	1997	_	_	
56-24	5949-5950	)	_	_	
56-25	5951-5959	Virology	_	_	
56-26	5960-5963	232	_	_	
56-27	5963-5964	:	_	_	
56-28	5965-5968	129	_	_	
56-29	5968-5969	-	_	_	
56-30	5969-5972	138	_	_	
56-31	5972-5973	;	_	_	
56-32	5974-5977	Jin	_	_	
56-33	5978-5980	et	_	_	
56-34	5981-5983	al	_	_	
56-35	5983-5984	.	_	_	
56-36	5985-5986	(	_	_	
56-37	5986-5990	1996	_	_	
56-38	5990-5991	)	_	_	
56-39	5992-5996	Arch	_	_	
56-40	5996-5997	.	_	_	

#Text=Virol. 141: 2057-2076); the E1, E2, E3, E4, E5, E6 and E7 proteins of human papillomavirus (Brown et al. (1994) Virology 201: 46-54; Dillner et al. (1995) Cancer Detect.
57-1	5998-6003	Virol	_	_	
57-2	6003-6004	.	_	_	
57-3	6005-6008	141	_	_	
57-4	6008-6009	:	_	_	
57-5	6010-6014	2057	_	_	
57-6	6014-6015	-	_	_	
57-7	6015-6019	2076	_	_	
57-8	6019-6020	)	_	_	
57-9	6020-6021	;	_	_	
57-10	6022-6025	the	_	_	
57-11	6026-6028	E1	_	_	
57-12	6028-6029	,	_	_	
57-13	6030-6032	E2	_	_	
57-14	6032-6033	,	_	_	
57-15	6034-6036	E3	_	_	
57-16	6036-6037	,	_	_	
57-17	6038-6040	E4	_	_	
57-18	6040-6041	,	_	_	
57-19	6042-6044	E5	_	_	
57-20	6044-6045	,	_	_	
57-21	6046-6048	E6	_	_	
57-22	6049-6052	and	_	_	
57-23	6053-6055	E7	_	_	
57-24	6056-6064	proteins	_	_	
57-25	6065-6067	of	_	_	
57-26	6068-6073	human	_	_	
57-27	6074-6088	papillomavirus	_	_	
57-28	6089-6090	(	_	_	
57-29	6090-6095	Brown	_	_	
57-30	6096-6098	et	_	_	
57-31	6099-6101	al	_	_	
57-32	6101-6102	.	_	_	
57-33	6103-6104	(	_	_	
57-34	6104-6108	1994	_	_	
57-35	6108-6109	)	_	_	
57-36	6110-6118	Virology	_	_	
57-37	6119-6122	201	_	_	
57-38	6122-6123	:	_	_	
57-39	6124-6126	46	_	_	
57-40	6126-6127	-	_	_	
57-41	6127-6129	54	_	_	
57-42	6129-6130	;	_	_	
57-43	6131-6138	Dillner	_	_	
57-44	6139-6141	et	_	_	
57-45	6142-6144	al	_	_	
57-46	6144-6145	.	_	_	
57-47	6146-6147	(	_	_	
57-48	6147-6151	1995	_	_	
57-49	6151-6152	)	_	_	
57-50	6153-6159	Cancer	_	_	
57-51	6160-6166	Detect	_	_	
57-52	6166-6167	.	_	_	

#Text=Prev. 19: 381-393; Krul et al. (1996) Cancer Immunol.
58-1	6168-6172	Prev	_	_	
58-2	6172-6173	.	_	_	
58-3	6174-6176	19	_	_	
58-4	6176-6177	:	_	_	
58-5	6178-6181	381	_	_	
58-6	6181-6182	-	_	_	
58-7	6182-6185	393	_	_	
58-8	6185-6186	;	_	_	
58-9	6187-6191	Krul	_	_	
58-10	6192-6194	et	_	_	
58-11	6195-6197	al	_	_	
58-12	6197-6198	.	_	_	
58-13	6199-6200	(	_	_	
58-14	6200-6204	1996	_	_	
58-15	6204-6205	)	_	_	
58-16	6206-6212	Cancer	_	_	
58-17	6213-6220	Immunol	_	_	
58-18	6220-6221	.	_	_	

#Text=Immunother. 43: 44-48; Nakagawa et al. (1997) J.
59-1	6222-6232	Immunother	_	_	
59-2	6232-6233	.	_	_	
59-3	6234-6236	43	_	_	
59-4	6236-6237	:	_	_	
59-5	6238-6240	44	_	_	
59-6	6240-6241	-	_	_	
59-7	6241-6243	48	_	_	
59-8	6243-6244	;	_	_	
59-9	6245-6253	Nakagawa	_	_	
59-10	6254-6256	et	_	_	
59-11	6257-6259	al	_	_	
59-12	6259-6260	.	_	_	
59-13	6261-6262	(	_	_	
59-14	6262-6266	1997	_	_	
59-15	6266-6267	)	_	_	
59-16	6268-6269	J	_	_	
59-17	6269-6270	.	_	_	

#Text=Infect.
60-1	6271-6277	Infect	_	_	
60-2	6277-6278	.	_	_	

#Text=Dis. 175: 927-931); a human T-lymphotropic virus type I gag protein (Porter et al. (1995) J.
61-1	6279-6282	Dis	_	_	
61-2	6282-6283	.	_	_	
61-3	6284-6287	175	_	_	
61-4	6287-6288	:	_	_	
61-5	6289-6292	927	_	_	
61-6	6292-6293	-	_	_	
61-7	6293-6296	931	_	_	
61-8	6296-6297	)	_	_	
61-9	6297-6298	;	_	_	
61-10	6299-6300	a	_	_	
61-11	6301-6306	human	_	_	
61-12	6307-6321	T-lymphotropic	_	_	
61-13	6322-6327	virus	_	_	
61-14	6328-6332	type	_	_	
61-15	6333-6334	I	_	_	
61-16	6335-6338	gag	_	_	
61-17	6339-6346	protein	_	_	
61-18	6347-6348	(	_	_	
61-19	6348-6354	Porter	_	_	
61-20	6355-6357	et	_	_	
61-21	6358-6360	al	_	_	
61-22	6360-6361	.	_	_	
61-23	6362-6363	(	_	_	
61-24	6363-6367	1995	_	_	
61-25	6367-6368	)	_	_	
61-26	6369-6370	J	_	_	
61-27	6370-6371	.	_	_	

#Text=Med.
62-1	6372-6375	Med	_	_	
62-2	6375-6376	.	_	_	

#Text=Virol. 45: 469-474); Epstein-Barr virus (EBV) gp340 (Mackett et al. (1996) J.
63-1	6377-6382	Virol	_	_	
63-2	6382-6383	.	_	_	
63-3	6384-6386	45	_	_	
63-4	6386-6387	:	_	_	
63-5	6388-6391	469	_	_	
63-6	6391-6392	-	_	_	
63-7	6392-6395	474	_	_	
63-8	6395-6396	)	_	_	
63-9	6396-6397	;	_	_	
63-10	6398-6410	Epstein-Barr	_	_	
63-11	6411-6416	virus	_	_	
63-12	6417-6418	(	_	_	
63-13	6418-6421	EBV	_	_	
63-14	6421-6422	)	_	_	
63-15	6423-6428	gp340	_	_	
63-16	6429-6430	(	_	_	
63-17	6430-6437	Mackett	_	_	
63-18	6438-6440	et	_	_	
63-19	6441-6443	al	_	_	
63-20	6443-6444	.	_	_	
63-21	6445-6446	(	_	_	
63-22	6446-6450	1996	_	_	
63-23	6450-6451	)	_	_	
63-24	6452-6453	J	_	_	
63-25	6453-6454	.	_	_	

#Text=Med.
64-1	6455-6458	Med	_	_	
64-2	6458-6459	.	_	_	

#Text=Virol. 50: 263-271); the Epstein-Barr virus (EBV) latent membrane protein LMP2 (Lee et al. (1996) Eur.
65-1	6460-6465	Virol	_	_	
65-2	6465-6466	.	_	_	
65-3	6467-6469	50	_	_	
65-4	6469-6470	:	_	_	
65-5	6471-6474	263	_	_	
65-6	6474-6475	-	_	_	
65-7	6475-6478	271	_	_	
65-8	6478-6479	)	_	_	
65-9	6479-6480	;	_	_	
65-10	6481-6484	the	_	_	
65-11	6485-6497	Epstein-Barr	_	_	
65-12	6498-6503	virus	_	_	
65-13	6504-6505	(	_	_	
65-14	6505-6508	EBV	_	_	
65-15	6508-6509	)	_	_	
65-16	6510-6516	latent	_	_	
65-17	6517-6525	membrane	_	_	
65-18	6526-6533	protein	_	_	
65-19	6534-6538	LMP2	_	_	
65-20	6539-6540	(	_	_	
65-21	6540-6543	Lee	_	_	
65-22	6544-6546	et	_	_	
65-23	6547-6549	al	_	_	
65-24	6549-6550	.	_	_	
65-25	6551-6552	(	_	_	
65-26	6552-6556	1996	_	_	
65-27	6556-6557	)	_	_	
65-28	6558-6561	Eur	_	_	
65-29	6561-6562	.	_	_	

#Text=J.
66-1	6563-6564	J	_	_	
66-2	6564-6565	.	_	_	

#Text=Immunol. 26: 1875-1883); Epstein-Barr virus nuclear antigens 1 and 2 (Chen and Cooper (1996) J.
67-1	6566-6573	Immunol	_	_	
67-2	6573-6574	.	_	_	
67-3	6575-6577	26	_	_	
67-4	6577-6578	:	_	_	
67-5	6579-6583	1875	_	_	
67-6	6583-6584	-	_	_	
67-7	6584-6588	1883	_	_	
67-8	6588-6589	)	_	_	
67-9	6589-6590	;	_	_	
67-10	6591-6603	Epstein-Barr	_	_	
67-11	6604-6609	virus	_	_	
67-12	6610-6617	nuclear	_	_	
67-13	6618-6626	antigens	_	_	
67-14	6627-6628	1	_	_	
67-15	6629-6632	and	_	_	
67-16	6633-6634	2	_	_	
67-17	6635-6636	(	_	_	
67-18	6636-6640	Chen	_	_	
67-19	6641-6644	and	_	_	
67-20	6645-6651	Cooper	_	_	
67-21	6652-6653	(	_	_	
67-22	6653-6657	1996	_	_	
67-23	6657-6658	)	_	_	
67-24	6659-6660	J	_	_	
67-25	6660-6661	.	_	_	

#Text=Virol. 70: 4849-4853; Khanna et al. (1995) Virology 214: 633-637); the measles virus nucleoprotein (N) (Fooks et al. (1995) Virology 210: 456-465); and cytomegalovirus glycoprotein gB (Marshall et al. (1994) J.
68-1	6662-6667	Virol	_	_	
68-2	6667-6668	.	_	_	
68-3	6669-6671	70	_	_	
68-4	6671-6672	:	_	_	
68-5	6673-6677	4849	_	_	
68-6	6677-6678	-	_	_	
68-7	6678-6682	4853	_	_	
68-8	6682-6683	;	_	_	
68-9	6684-6690	Khanna	_	_	
68-10	6691-6693	et	_	_	
68-11	6694-6696	al	_	_	
68-12	6696-6697	.	_	_	
68-13	6698-6699	(	_	_	
68-14	6699-6703	1995	_	_	
68-15	6703-6704	)	_	_	
68-16	6705-6713	Virology	_	_	
68-17	6714-6717	214	_	_	
68-18	6717-6718	:	_	_	
68-19	6719-6722	633	_	_	
68-20	6722-6723	-	_	_	
68-21	6723-6726	637	_	_	
68-22	6726-6727	)	_	_	
68-23	6727-6728	;	_	_	
68-24	6729-6732	the	_	_	
68-25	6733-6740	measles	_	_	
68-26	6741-6746	virus	_	_	
68-27	6747-6760	nucleoprotein	_	_	
68-28	6761-6762	(	_	_	
68-29	6762-6763	N	_	_	
68-30	6763-6764	)	_	_	
68-31	6765-6766	(	_	_	
68-32	6766-6771	Fooks	_	_	
68-33	6772-6774	et	_	_	
68-34	6775-6777	al	_	_	
68-35	6777-6778	.	_	_	
68-36	6779-6780	(	_	_	
68-37	6780-6784	1995	_	_	
68-38	6784-6785	)	_	_	
68-39	6786-6794	Virology	_	_	
68-40	6795-6798	210	_	_	
68-41	6798-6799	:	_	_	
68-42	6800-6803	456	_	_	
68-43	6803-6804	-	_	_	
68-44	6804-6807	465	_	_	
68-45	6807-6808	)	_	_	
68-46	6808-6809	;	_	_	
68-47	6810-6813	and	_	_	
68-48	6814-6829	cytomegalovirus	_	_	
68-49	6830-6842	glycoprotein	_	_	
68-50	6843-6845	gB	_	_	
68-51	6846-6847	(	_	_	
68-52	6847-6855	Marshall	_	_	
68-53	6856-6858	et	_	_	
68-54	6859-6861	al	_	_	
68-55	6861-6862	.	_	_	
68-56	6863-6864	(	_	_	
68-57	6864-6868	1994	_	_	
68-58	6868-6869	)	_	_	
68-59	6870-6871	J	_	_	
68-60	6871-6872	.	_	_	

#Text=Med.
69-1	6873-6876	Med	_	_	
69-2	6876-6877	.	_	_	

#Text=Virol. 43: 77-83) or glycoprotein gH (Rasmussen et al. (1994) J.
70-1	6878-6883	Virol	_	_	
70-2	6883-6884	.	_	_	
70-3	6885-6887	43	_	_	
70-4	6887-6888	:	_	_	
70-5	6889-6891	77	_	_	
70-6	6891-6892	-	_	_	
70-7	6892-6894	83	_	_	
70-8	6894-6895	)	_	_	
70-9	6896-6898	or	_	_	
70-10	6899-6911	glycoprotein	_	_	
70-11	6912-6914	gH	_	_	
70-12	6915-6916	(	_	_	
70-13	6916-6925	Rasmussen	_	_	
70-14	6926-6928	et	_	_	
70-15	6929-6931	al	_	_	
70-16	6931-6932	.	_	_	
70-17	6933-6934	(	_	_	
70-18	6934-6938	1994	_	_	
70-19	6938-6939	)	_	_	
70-20	6940-6941	J	_	_	
70-21	6941-6942	.	_	_	

#Text=Infect.
71-1	6943-6949	Infect	_	_	
71-2	6949-6950	.	_	_	

#Text=Dis. 170: 673-677).
72-1	6951-6954	Dis	_	_	
72-2	6954-6955	.	_	_	
72-3	6956-6959	170	_	_	
72-4	6959-6960	:	_	_	
72-5	6961-6964	673	_	_	
72-6	6964-6965	-	_	_	
72-7	6965-6968	677	_	_	
72-8	6968-6969	)	_	_	
72-9	6969-6970	.	_	_	
